These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

284 related articles for article (PubMed ID: 10772564)

  • 1. Immunogenicity and safety of a new inactivated hepatitis A vaccine in Thai young adults.
    Vimolket T; Theamboonlers A; Dumas R; Milcamps B; Forrat R; Poovorawan Y
    Southeast Asian J Trop Med Public Health; 1998 Dec; 29(4):779-85. PubMed ID: 10772564
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Immunogenicity and safety of an inactivated hepatitis A vaccine in Taiwanese adults and children.
    Lee CY; Huang LM; Lee PI; Chiu HH; Dumas R; Milcamps B; Lin W
    Southeast Asian J Trop Med Public Health; 2000 Mar; 31(1):29-36. PubMed ID: 11023061
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Evaluation of immunogenicity and safety in healthy adults of an inactivated anti-hepatitis A vaccine].
    Gil A; González A; Dal-Ré ; Aguilar L; Malo C; del Rey J
    Med Clin (Barc); 1994 May; 102(20):769-71. PubMed ID: 8041214
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical trial to evaluate immunogenicity and safety of inactivated hepatitis A vaccination starting at 2-month-old children.
    Kanra G; Yalçin SS; Ceyhan M; Yurdakök K
    Turk J Pediatr; 2000; 42(2):105-8. PubMed ID: 10936974
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Immunogenicity, safety, and interchangeability of two inactivated hepatitis A vaccines in Chilean children.
    Abarca K; Ibánez I; Perret C; Vial P; Zinsou JA
    Int J Infect Dis; 2008 May; 12(3):270-7. PubMed ID: 17988917
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Evaluation of inactivated hepatitis A vaccine in Canadians 40 years of age or more.
    Scheifele DW; Bjornson GJ
    CMAJ; 1993 Feb; 148(4):551-5. PubMed ID: 8431816
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Safety and immunogenicity of a new inactivated hepatitis A vaccine].
    Ren A; Ma J; Feng F
    Zhonghua Shi Yan He Lin Chuang Bing Du Xue Za Zhi; 2001 Dec; 15(4):357-9. PubMed ID: 11986726
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Immunogenicity and safety of an inactivated hepatitis A vaccine amongst Singaporeans.
    Guan R; Ng HS; Fock KM; Ho KY; Yap I; Kang JY; Chow WC; Chew CN; Ng C; Teo CJ
    Southeast Asian J Trop Med Public Health; 1995 Jun; 26(2):268-71. PubMed ID: 8629058
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [The study on the 0, 12 month vaccination schedule' of Healive inactivated hepatitis A vaccine in children].
    Ren YH; Chen JT; Wu WT; Gong XJ; Zhang YC; Xue WH; Ren YF; Han LJ; Kang WX; Li SP; Liu CB
    Zhonghua Liu Xing Bing Xue Za Zhi; 2003 Nov; 24(11):1013-5. PubMed ID: 14687502
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Clinical development of a new inactivated hepatitis A vaccine].
    Vidor E; Saliou P
    Sante; 1998; 8(5):361-8. PubMed ID: 9854014
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Vaccination against viral hepatitis A and B in adults aged over 40 years--antibody persistence and immune memory].
    Chlibek R; Smetana J; Bostíková V; Splino M
    Epidemiol Mikrobiol Imunol; 2011 Sep; 60(3):99-108. PubMed ID: 22132651
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Immunogenicity and reactogenicity of an inactivated hepatitis A vaccine in Indian adults.
    Das K; Jain A; Gupta RK; Kar P
    Natl Med J India; 1999; 12(6):268-9. PubMed ID: 10732428
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Virosomal hepatitis a vaccine: comparing intradermal and subcutaneous with intramuscular administration.
    Frösner G; Steffen R; Herzog C
    J Travel Med; 2009; 16(6):413-9. PubMed ID: 19930383
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Immunogenicity and safety of a virosomal hepatitis A vaccine (Epaxal) in the elderly.
    D'Acremont V; Herzog C; Genton B
    J Travel Med; 2006; 13(2):78-83. PubMed ID: 16553593
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Single dose-inactivated hepatitis A vaccination schedule for susceptible youngsters.
    Lee SD; Chan CY; Yu MI; Wang YJ; Lo KJ; Safary A
    Am J Gastroenterol; 1996 Jul; 91(7):1360-2. PubMed ID: 8677995
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Rapid antibody response after vaccination with a virosomal hepatitis a vaccine.
    Ambrosch F; Finkel B; Herzog C; Koren A; Kollaritsch H
    Infection; 2004 Jun; 32(3):149-52. PubMed ID: 15188074
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Analysis of the antibody response in humans with a new inactivated hepatitis A vaccine.
    Vidor E; Xueref C; Blondeau C; Bajard A; Francon A; Goudeau A; Peyron F; Brasseur P; Zuckerman A
    Biologicals; 1996 Sep; 24(3):235-42. PubMed ID: 8978923
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A trial of the reactogenicity and immunogenicity of an inactivated hepatitis A vaccine.
    Green MS; Cohen D; Lerman Y; Sjogren M; Binn LN; Zur S; Slepon R; Robin G; Hoke C; Bancroft W
    Isr J Med Sci; 1994; 30(5-6):485-8. PubMed ID: 8034508
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Hepatitis A booster vaccine in children after infant immunization.
    Kanra G; Yalcin SS; Kara A; Ozmert E; Yurdakök K
    Pediatr Infect Dis J; 2002 Aug; 21(8):727-30. PubMed ID: 12192159
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Immunogenicity of an inactivated hepatitis A pediatric vaccine: three-year post-booster follow-up.
    Dagan R; Greenberg D; Weber F
    Vaccine; 2005 Oct; 23(44):5144-8. PubMed ID: 16043271
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.